Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03698669 · ClinicalTrials.gov registry record · NA
Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings
A NA study, sponsored by Boston University.
- Completed
- Registry status
- NA
- Development phase
- 163
- Enrollment target
NCT03698669 is a NA study that has completed, run by Boston University. The registered enrollment target is 163 participants.
The verdict
NCT03698669, a NA study, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- NA
- Development phase
- 163 participants
- Enrollment target
Study Summary
Treating Opioid Patients' Pain and Sadness (TOPPS) focuses on the relationship of pain, depression, opioid and other substance misuse, and functioning. It has a structured agenda, uses behavioral activation, involves explicit and ongoing psychoeducation, and includes a behavioral health specialist (BHS) trained extensively in the nature of pain and opioid misuse, including how to assess for red flags of opioid relapse. Devised specifically for primary care patients receiving buprenorphine, TOPPS is collaborative (PCP, BHS, and patient) and focuses on pain and physical symptoms in order to decrease the need to turn to substance misuse to avoid pain, and to foster patient's abilities to achieve their long-term life goals. In this study, TOPPS is compared to a health education contact-control condition among 250 persons with opioid use disorder recruited from two primary care based buprenorphine programs. The investigators will provide both interventions over 3 months, and follow the patients for a total of 12 months in order to observe both short-term and longer-term effects of TOPPS.
Interventions
- BEHAVIORAL Health Education (HE)
- BEHAVIORAL Treating Opioid Patients' Pain and Sadness (TOPPS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2019-08-21 |
| Est. Completion | 2024-12-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03698669
The ClinicalTrials.gov registry entry for NCT03698669 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Health Education (HE) is the first listed.
NCT03698669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03698669 about?
NCT03698669 is a clinical study titled "Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings". Treating Opioid Patients' Pain and Sadness (TOPPS) focuses on the relationship of pain, depression, opioid and other substance misuse, and functioning. It has a structured agenda, uses behavioral activation, involves explicit and ongoing psychoeducation, and includes a behavioral health specialist (...
What is the current status of trial NCT03698669?
This trial is currently completed. It is a NA study. The enrollment target is 163 participants. The study started on 2019-08-21. Estimated completion is 2024-12-20.
What interventions are being tested in trial NCT03698669?
The interventions under investigation include: Health Education (HE) (BEHAVIORAL), Treating Opioid Patients' Pain and Sadness (TOPPS) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03698669?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.